•
Jun 30, 2021
Rigel Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $13.8 million for the second quarter of 2021, with total revenues of $26.3 million, including TAVALISSE net product sales of $17.1 million.
TAVALISSE sales are growing as Rigel accesses more clinicians in-person.
Rigel is expanding its commercial team to increase impact as physicians and patients return to the clinic.
Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients is rapidly enrolling.
Phase 3 clinical trial of fostamatinib in wAIHA is nearing its enrollment goal.
Rigel
Rigel
Rigel Revenue by Segment
Forward Guidance
Rigel is well-positioned to execute on several key milestones that have the potential to be important inflection points for the company.